Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
Organon (NYSE: OGN), a global healthcare company focused on improving women’s health, today announced the launch of a new global initiative, “Her Plan is Her Power,” to accelerate progress toward addressing the public health crisis of unplanned pregnancy. Annually, nearly 50% of pregnancies (approximately 121 million) around the world are estimated to be unplanned, leading to health risks and reduced educational and employment opportunities for mother and child – challenges which can span generations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230307005176/en/
Unplanned pregnancies are in part caused by a lack of access to contraceptive information and services. Globally, of the 257 million women who want to avoid pregnancy, almost 67% are not using any contraceptive method. In response, Organon’s multi-year effort (2023-2025) builds on previous programming launched in 2022 through the “Her Promise” ESG platform. This new effort includes a portfolio of programs, collaborations and investments designed to fuel public health solutions, address inequities, and accelerate progress to help ensure women have the power to plan their future.
The $30 million “Her Plan is Her Power” initiative aims to address and overcome gaps and barriers to reduce unplanned pregnancies and empower women and girls when it comes to their sexual and reproductive health (SRH). It builds on existing company initiatives, with new funding to support:
- A planned three-pronged collaboration with UNFPA, the United Nations sexual and reproductive health agency, to help reduce unplanned pregnancies focused on innovation, access and education, and financing and sustainability. Initial projects are planned to support the Equalizer: UNFPA Accelerator Fund, through the establishment of an innovation challenge to empower young people by increasing access to financing and training to enable innovations for SRH information, services and commodities; enhancing a digital SRH knowledge solution with ethical artificial intelligence capabilities to give information and analytics to frontline healthcare workers in low-resource settings; and support for the Equity 2030 Alliance to accelerate actions to normalize gender equity in science and technology with a focus on SRH and women-focused solutions.
- Inaugural launch of a global grants program that provides resources to organizations working in communities to create a local response and empower people when it comes to reducing unplanned pregnancies and taking control of their reproductive health. The first cohort of grantees includes organizations across 13 countries including Dominican Republic, South Korea, Germany, and Thailand.
- New funding and product donations to help improve access and outcomes related to unplanned pregnancy in select communities in the US. Initial planned NGO partners include Direct Relief and Power to Decide, with additional US-based organizations and communities to be announced later this year.
“Empowering women with broad contraceptive access and education is a fundamental driver of equity and helping women decide when – and if – they decide to start a family,” said Kevin Ali, CEO of Organon. “Organon is proud to launch ‘Her Plan is Her Power’ and work with others to focus our resources and target responses to help ensure all women and girls can plan their future.”
This announcement comes on International Women’s Day and on the sidelines of the 67th session of the United Nations Commission on the Status of Women, to raise awareness and spur action, because in this complex environment, there has never been a more critical moment to stand – and act – with her.
“UNFPA is very excited to be working with Organon to advance sexual and reproductive health and rights and choices,” says Ian McFarlane, the Director of the Division for Communications and Strategic Partnerships at UNFPA. “The staggering number of unintended pregnancies that occur globally each year – nearly half of all pregnancies – require the power of public-private collaboration. We look forward to continuing to build upon our efforts to help improve the lives of women and girls around the world.”
Organon is working to ensure that all women and girls achieve the full potential of their promise through better health. In 2022, Organon made a commitment to help prevent 120 million unplanned pregnancies in the world’s least-developed countries by 2030 as part of FP2030. Through “Her Plan is Her Power” the company will further accelerate progress towards this goal by working with global and local organizations across geographies with a focus on innovation, education, access, and advocacy.
About Organon
Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon’s existing products produce strong cash flows that support investments in innovation and future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.
For more information, visit https://www.organon.com/ and connect with us on LinkedIn, Instagram, Twitter and Facebook.
Forward-Looking Statement
Except for historical information herein, this press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about Organon’s launch of the “Her Plan is Her Power” global initiative. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission ("SEC"), including the company’s Annual Report on Form 10-K for the year ended December 31, 2022, available at the SEC’s Internet site (www.sec.gov).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005176/en/
Contact information
Media:
Karissa Peer
(614) 314-8094
Joanna Breitstein
(347) 820-4046
Investor:
Jennifer Halchak
(201) 275-2711
Alex Arzeno
(203) 550-3972
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Tourism Surging Ahead of Economic Growth, With Visits to Hit 30 Billion by 20344.7.2025 02:00:00 EEST | Press release
The World Economic Forum has today published a new report forecasting that the travel and tourism industry is projected to serve 30 billion tourist trips by 2034. Travel and Tourism at a Turning Point: Principles for Transformative Growth, produced in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, reveals a projected $16 trillion contribution to global GDP by the same year—representing more than 11% of the total world economy, according to World Travel & Tourism Council estimates. The report also found that the sector is expanding 1.5 times faster than the global economy, generating significant commercial opportunities as long as the mounting challenges of climate change, labour shortages and infrastructure gaps are addressed. Inbound and outbound trips increasing fast Asia is on track to become the world’s fastest-growing tourism economy, with the direct travel and tourism GDP contribution expected to exceed 7% across the region by 2034. Notably, India and China
The 2025-2026 World Branding Awards Animalis Edition Honouring Leading Pet and Animal Brands Globally3.7.2025 22:00:00 EEST | Press release
The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from all around the world. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. “The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry,” said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominate
Venture Global Announces 20-Year Sales and Purchase Agreement with PETRONAS3.7.2025 15:59:00 EEST | Press release
Today, Venture Global, Inc. (NYSE: VG) announced the execution of a new 20-year Sales and Purchase Agreement (SPA) with PETRONAS LNG Ltd. (PLL), a subsidiary of the Malaysian state-owned oil and gas company, PETRONAS. Under the terms of the SPA, PETRONAS will purchase 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global’s third facility, CP2 LNG, for 20 years. This builds upon Venture Global’s existing agreement with PETRONAS for 1 MTPA of LNG supply from Plaquemines LNG. PETRONAS, a world-class partner in the LNG industry, joins other CP2 LNG customers in Europe, Asia and the rest of the world in a strategically important project to global energy supply and security. To date, approximately 10.75 MTPA of the 14.4 MTPA nameplate capacity for CP2 Phase One has been sold. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets ac
Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year3.7.2025 15:05:00 EEST | Press release
In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703950144/en/ Novotech Wins Global CRO Award Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies. “Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for
Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model3.7.2025 13:02:00 EEST | Press release
The novel compound AC102 almost completely reversed tinnitus in a preclinical model after a single dose. At the same time, the damaged connections between the auditory nerve and inner ear sensory cells were restored. These findings were recently published in the prestigious International Journal of Molecular Sciences in a joint study conducted by Erlangen University Hospital and Berlin-based drug developer AudioCure. As there is currently no causal treatment for tinnitus, there is a high medical need. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702168211/en/ In 10-20% of tinnitus cases, the noise in the ear is so severe that it significantly impairs the quality of life of those affected. (Source: AI-generated) In the current study, AC102 was administered to the middle ear of one experimental group after acoustic trauma, while a second group received a placebo. Although both groups initially showed signs of tinnitus, th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom